With no “cure,” neovascular age-related macular degeneration (or wet AMD) remains a key disease state for numerous pharmaceutical companies.
Michelle Dalton, ELS
About 85% to 90% of the cases of age-related macular degeneration (AMD) are the “dry” (atrophic) type.
The year 2018 had its share of groundbreaking research in age-related macular degeneration (AMD). Here is a brief overview of what’s been presented or published within the past 12 months.
More and more companies are looking for novel ways to educate both eye-care professionals and patients about age-related macular degeneration (AMD).
Below are a few of the newer training materials available.
Age-related macular degeneration (AMD) affects more than 10 million Americans, and the risk of developing AMD is increased when there is a family history.
Fifteen fellows, residents showed just why research in retina is on the cutting edge
Numerous websites are designed to raise awareness about age-related macular degeneration (AMD), some sponsored by the National Eye Institute, others by disease-specific foundations, and others by industry.
From the latest ADA position statements to special issues to dietary intake, here’s the latest info to share with your patients about diabetic eye disease.
About 33% of patients with diabetes have diabetic retinopathy (DR), and, of those, 7% will progress to diabetic macular edema (DME).1 Patients with DR and/or DME incur significant medical costs.
About 33% of patients with diabetes have some level of diabetic retinopathy (DR), and, of those, 7% will progress to diabetic macular edema (DME).1 Medical therapies have decreased the severity of DME and DR in recent years, an